So the Biogen relationship..
Biogen needs something for als..
Probably just conceding or selling this to them .. makes sense.. they would have been a very competitive force against Neuro..so capitulation makes sense..
I would have a third party double check their data tests..
No really.. I would be sending the samples to a third party and PAYING for verification and NOT solely relying on bioscam..
Anavex has a miracle drug call Blarcamesine
Early on they made the mistake of opening the door to Biogen with als co research with Biogen..
Wayne state did a study the drug worked great for als..
Nothing .. nothing..
Blarcamesine still isn’t approved ( 10 years later) while Biogen has ad drugs approved that are dangerous and do nothing.
Anavex hasn’t wandered any deeper into als.. and anavex stock has been undervalued for almost the entire time they have had a Biogen relationship.
Personally I see Biogen as I see Pfizer
Neither gives a crap about human life or health..
Why is doing business with Biogen so bad?
What experience/example can you relate to?
I was interested in getting some shares but reading your posts it may not be a good idea.
I am a bit confused here, maybe I don't understand the issue.
If the relationship goes well they might do something like
Short your stock so you lose your investor base and ability to reside money
Than make you a chump change offer because you are out of money..
Would never do business with amoral people..
Good bye Nrsn
Just saw it’s an engagement with bioscam..
Who would willingly do business with Biogen?
Some news on watch again
Probaby time for another 424B3 shelf placement!
NeuroSense Therapeutics Sees Positive Trial Results for TDP-43 Alzheimer's Treatment
9:03 am ET January 19, 2023 (Dow Jones) Print
By Chris Wack
NeuroSense Therapeutics Ltd. said it saw positive final results from a biomarker study conducted to evaluate the potential of NeuroSense's combination platform therapy for the treatment of Alzheimer's disease.
The company said preliminary results from the study showed that TDP-43, a novel biomarker, was elevated in Alzheimer's disease patients compared with a healthy control group.
Based on these preliminary results, NeuroSense said it expanded the study with a larger healthy control group to further validate the results.
NeuroSense's platform combination therapy technology has already shown a statistically significant reduction of TDP-43 in a Phase 2a clinical trial biomarker study in another neurodegenerative disease, amyotrophic lateral sclerosis, and is now being evaluated in a Phase 2b ALS double-blind clinical trial.
The company plans to start a Phase 2 double-blind proof-of-concept study in Alzheimer's disease in the first half of 2023.
Thanks so much, buddy. Wishing you all the very best to come
No worries. Good luck with all your trades.
Sorry, bro, many others will pop. Biotechs heating hup after a long slump.
Saw this. Unfortunately, I clipped it yesterday. Left a bunch on the table. This is not unusual lol. You're welcome. $NSRN.
Good morning Franky buddy. It's payday baby!
NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer's Biomarker Study
Biomarkers show the potential of NeuroSense's combination drug CogniC to treat Alzheimer's disease
CogniC is expected to advance into clinical trials in 2023
CAMBRIDGE, Mass., June 30, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced results from a biomarker study conducted to evaluate the potential of CogniC, NeuroSense's combination drug for the treatment of Alzheimer's disease (AD).
NeuroSense's biomarker study identified several biomarkers associated with AD, which indicate CogniC's mechanism of action may be effective in targeting the pathways involved in the disease, such as miRNA dysregulation, lysosomal dysfunction, and impaired autophagy. Additionally, hallmarks of AD were detected, such as increased levels of amyloid-ß (Aß) and intracellular aggregates of tau protein among the panel of biomarkers evaluated.
Preliminary results revealed high levels of TDP-43 in people who suffer from AD, when compared to the healthy control group. These findings provide additional support for TDP-43 pathology as an integral part of AD, reinforcing the growing body of evidence in AD research regarding the role of TDP-43 in neurodegenerative pathologies. TDP-43 has been found in up to 57% of AD cases and aggregates of TDP-43 have been shown to be cytotoxic both in vitro and in vivo.  NeuroSense's platform combination therapy technology, the basis of CogniC, has already shown to impact TDP-43 in a Phase IIa clinical trial biomarker study in another neurodegenerative disease, amyotrophic lateral sclerosis (ALS).
"Having identified these promising biomarkers, which have the potential to be modulated by CogniC, we are now preparing to carry out a clinical proof-of-concept study in conjunction with a leading AD clinic. The study is expected to commence in 2023," stated NeuroSense CEO, Alon Ben-Noon.
NeuroSense is conducting its AD biomarker study via utilization of Neuron-Derived Exosomes (NDE), a cutting-edge technology which allows one to observe key alterations in biomarkers found in the central nervous system in a non-invasive manner via collection of blood samples. Following further analysis, NeuroSense expects to share more detailed results on additional novel biomarkers that were evaluated in this study through scientific conferences and peer-reviewed publications.
Transactive response DNA binding protein of 43 kDa (TDP-43) is involved in regulation of gene expression. AD patients with TDP-43 pathology have increased severity of cognitive impairment compared to those without TDP-43 pathology. Additionally, the strongest genetic risk factor for AD, apolipoprotein E4 (APOE4), is associated with increased frequency of TDP-43 pathology.
About Alzheimer's Disease
Alzheimer's disease (AD) is a brain disorder that slowly destroys memory and thinking skills. AD is the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer's disease accounts for 60-80% of dementia cases. The global AD treatment market is expected to grow to $5 billion in 2022.
CogniC is a combination drug for the treatment of Alzheimer's disease and is based on NeuroSense's combina
NRSN is running hot on the RSI for good reason. NRSN is creating novel treatments. It's a new path forward in an otherwise, sort of maxed approach. It appears NRSN's contribution stabilizes the disease rather than continuing downward with standards of (current) care, if I understand this correctly. These results (and anytime they'll drop the alz and parkinsons biomarker data) are VERY significant for the neurological field in general. It appears NRSN's contribution is statistically significant and everyone loves that! Stabilizing! It's going to be bumpy but up we will go! They slammed the heck out of this today but there is absolutely no way, NRSN stays below $5-$6 soon. These findings are absolutely amazing in nature. The stock continues to trend and the shorts that love biotechs (especially) will be blown away once this thing really takes off. Those days are upon us now, and it'll only get louder and more exciting in here! They've got almost $14 million in cash and a pipeline that is PRODUCING! Tough to find these days; especially in such an important arena. They're improving terrible, debilitating diseases right before our eyes. Terrific findings reported and will continue! Best to all!
Ty. Good to see you too. Let's make bank
Hi franky, great to see you! Yea this babe just got a pin in her ass! Screaming higher!
Wow! Finally moving. I mean ALS...Come on man! It's major good news
Yup and now starting to get more investor interest
Cool. Seeing a small spike premarket. $NRSN
NeuroSense Therapeutics reports completion of the "in-life" phase of its 90-day GLP Toxicology study successfully. All animals appeared normal, with no significant findings observed. In this study the components of PrimeC, celecoxib and ciprofloxacin, were administered to rodents at doses 4x the maximal clinical dose. The company will present the data obtained in this study to the FDA as part of PrimeC's drug development plan.
Exactly! Nice to meet you!
Great spike up today! Protect profits... especially in this market..
NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study
Preliminary results show levels of disease-related biomarkers remain unchanged in people living with ALS who are treated with standard of care, in contrast to the statistically significant decline in these biomarkers in patients treated in NeuroSense's Phase IIa study with PrimeC
New biomarker data in people with ALS validates NeuroSense's clinical strategy
CAMBRIDGE, Mass., June 27, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced results from Stage III of its biomarker study conducted in collaboration with Massachusetts General Hospital (MGH) to evaluate PrimeC, NeuroSense's lead combination drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). PrimeC is currently being evaluated in NeuroSense's Phase IIb PARADIGM study following the successful conclusion of its Phase IIa study which met its primary endpoints.
The purpose of the initial ALS biomarker study (Stage I) was to characterize the baseline phenomena observed in people living with ALS. The study identified novel ALS biomarkers that are indicative of PrimeC's mechanism of action (MOA), via an analysis comparing blood samples obtained from healthy people and from people living with ALS. TDP-43 accumulation and neuroinflammation via prostagladin2 were amongst the disease-modifying targets characterized, along with miRNA dysregulation, iron accumulation, lysosomal dysfunction, and impaired autophagy.
Stage II investigated the therapeutic effect of PrimeC. In NeuroSense's Phase IIa study, blood samples were analyzed to determine the longitudinal effect of PrimeC on the biomarkers identified in Stage I. Following 12 months of administration with PrimeC, statistically significant changes in key ALS-related biomarkers were observed in study participants. Furthermore, the study established a correlation between the clinically meaningful outcomes detected and modulations in those biomarkers.
The Stage III natural history study analyzed blood samples from people living with ALS, treated with standard of care. Preliminary results show that levels of disease-related biomarkers remain steady and unchanged in people living with ALS, in contrast to the statistically significant decline portrayed in these biomarkers when PrimeC was administered in addition to the standard of care. Stage III results further confirmed PrimeC's MOA, and expanded insight into ALS-related biomarkers and their correlation to the progression of ALS symptoms.
"These results are very encouraging, especially in that they validate NeuroSense's clinical strategy. The biomarker study, along with the data we collect from our Phase IIb study, will inform the optimization of a pivotal Phase III study of PrimeC in ALS," stated NeuroSense's CEO, Alon Ben-Noon. "NeuroSense is honored to collaborate with the world-class MGH team on this critical study."
"NeuroSense remains at the forefront of biomarker research with the inclusion of a comprehensive portfolio of biomarkers in our Phase IIb study. This is essential in exploring mechanistic associations in ALS," stated Dr. Shiran Zimri, Head of Scientific Programs at NeuroSense. "The use of neuronal derived exosomes (NDE), a cutting-edge technology, allows one to observe key alterations in biomarkers found in the central nervous system. We look forward to sharing more detailed results at the upcoming World Orphan Drug Congress in Boston, Massachusetts on July 11-13th."
PrimeC, NeuroSense's lead drug candidate is a combination therapy that was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). NeuroSense completed a Phase IIa clinical study which successfully met its safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biological markers indicating PrimeC's biological activity. Through a collaboration with Massachusetts General Hospital in Boston on novel Neuron-Derived Exosomes (NDEs), NeuroSense is working to further analyze the results and correlations to the clinical data, to determine the biological changes in ALS-related pathologies and the magnitude of the effect of PrimeC on relevant targets.
Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 patients are diagnosed with ALS in the U.S. alone, with an
$NRSN due for a run with the bouncing market
NASDAQ 2M nano-float, 11M O/S
ALS study updates to come https://finance.yahoo.com/news/neurosense-enrolls-first-patient-phase-123000179.html